Optimizing Trikafta Prior Authorization for Dermatology Practices

The Impact of High-Volume Specialty Drugs on Dermatology PA

Trikafta represents a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. For dermatology practices, managing such specialty drug PAs adds to an already complex landscape dominated by biologics for conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa, alongside procedures such as Mohs surgery. The administrative burden can divert staff from patient care and delay essential treatments.

Navigating Dermatology Prior Authorization Complexities

Dermatology prior authorizations are characterized by intricate payer policies for biologics and specialty drugs. Practices must contend with diverse requirements across various payer portals and channels, often involving detailed clinical criteria. This complexity extends to procedures such as Mohs micrographic surgery, which frequently triggers PA based on site and tumor characteristics.

Essential Documentation for Dermatology Prior Authorizations

• Diagnosis criteria and severity scores (e.g., PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis).
• Documentation of prior topical therapy trials and phototherapy trials where applicable.
• Evidence of prior conventional systemic therapy trials (e.g., methotrexate, cyclosporine) for certain biologics.
• Pre-biologic screenings for conditions like TB and and hepatitis.
• Conformance with AAD Appropriate Use Criteria (AUC) for procedures such as Mohs surgery.
• Age-appropriate criteria for specific biologic indications.

Mitigating Frequent Dermatology PA Denials

• Failure to document step therapy compliance for biologics (e.g., lack of prior conventional therapy trial).
• Insufficient documentation of disease severity (missing PASI, EASI, or BSA scores).
• Mismatch between Mohs surgery indications and AAD AUC.
• Gaps in required pre-biologic screenings (e.g., TB, hepatitis).
• Payer preference for biosimilar substitution over originator biologics.

Klivira's Solution for Dermatology Prior Authorization Automation

Klivira's platform is engineered to address the specific workflow constraints and documentation demands of dermatology practices. By integrating with EMRs via standards like SMART on FHIR, Klivira automates the submission and tracking of prior authorizations for high-volume specialty drugs and procedures. Our system incorporates AAD-guideline-aware step-therapy logic, AUC validation for Mohs surgery, and robust support for periodic re-authorization cycles, reducing manual effort and accelerating approvals.

Streamlining Workflow for Chronic Biologic Treatments

Dermatology practices frequently manage patients on chronic biologic therapies requiring periodic re-authorization, typically on 6 or 12-month cycles. Klivira's platform provides a structured workflow to manage these recurring PAs, distinguishing between medical and pharmacy benefit routing for self-injected versus clinic-infused medications. This ensures timely renewals and minimizes treatment interruptions, improving patient continuity of care and practice efficiency.